Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 7/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25920821 | 0.90 | TRPV1 (0.47) | TRPV1HDAC1HDAC3HDAC2NCOR2 | |
| SCHEMBL25929480 | 0.86 | SLC16A3 (0.41) | HDAC1HDAC3HDAC2NCOR2MAPT | |
| SCHEMBL24124859 | 0.81 | TRPV1 (0.52) | TRPV1HDAC1HDAC3HDAC2NCOR2 | |
| SCHEMBL25922362 | 0.80 | HDAC1 (0.42) | TRPV1HDAC1HDAC3HDAC2NCOR2 | |
| SCHEMBL25924692 | 0.78 | HDAC1 (0.66) | TRPV1HDAC1HDAC3HDAC2NCOR2 | |
| SCHEMBL24124938 | 0.77 | HDAC1 (0.49) | HDAC1HDAC3HDAC2NCOR2MAPT | |
| SCHEMBL25922356 | 0.76 | MAPK1 (0.59) | MAPTLMNAALDH1A1MEN1KMT2A | |
| SCHEMBL24124692 | 0.76 | TRPV1 (0.48) | TRPV1LMNAALDH1A1TP53MEN1 | |
| SCHEMBL24124334 | 0.75 | TRPV1 (0.49) | TRPV1MAPTTP53MEN1KMT2A | |
| SCHEMBL25921132 | 0.75 | GPR27 (0.61) | TRPV1MAPTLMNAALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242496-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-08-03 | — | — | US | disclosed |
| WO-2021257544-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2021-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242496-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | BCL6, SOX18, BCL3 | TRPV1 4833/4885HDAC1 898/4885HDAC3 1997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.